Hovione Technology unveils collaboration for new asthma product in Turkey
.jpg)
PowdAir Plus Dry Powder Inhaler.
Ventofor Combi Fix delivered by the PowdAir Plus dry powder inhaler.
Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and Hovione Technology, a pharmaceutical specialist in the development of innovative pulmonary device technology, have unveiled a collaboration supporting Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix, a formulation of budesonide formoterol for asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).
In Turkey, there is growing patient demand for effective, readily accessible and affordable respiratory treatments.
Aiming at fulfilling these patient needs, the three companies have been collaborating in Bilim Pharmaceuticals’ development program to bring into the Turkish market Ventofor Combi Fix delivered by the PowdAir Plus DPI (dry powder inhaler), an innovative capsule DPI providing maximum simplicity, ease of use and affordability.
The PowdAir Plus DPI is exclusively manufactured and commercialized by H&T Presspart under patent license from Hovione Technology.
“We are delighted to have started an inhalation collaboration with Bilim Pharmaceuticals and that they selected our PowdAir Plus DPI to bring Ventofor Combi Fix to patients’ hands. We are also happy to continue our partnership with H&T Presspart to turn our patented inhaler technology into a commercial-ready product that is now globally available to pharmaceutical companies,” said Peter Villax, Hovione Technology’s CEO.
Related News
-
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
.png)
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
.png)
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance